Aspire BioPharma is trading 5% up at $8.61, though no clear company-specific catalyst was identified for September 16, 2026.

  • Latest located corporate announcements were the September 8 name change and September 9 authorization of a $10 million stock-repurchase program; both are dated rather than fresh explanations.
  • Biotech is weakening overall, while major indexes are modestly higher, leaving the intraday gain unexplained.